GeNeuro Delays Half-Year Financial Report Release

GeNeuro SA, a biopharmaceutical company based in Geneva, announced the postponement of its half-year financial report for June 30, 2025. This delay aligns with the previous deferment of their annual financial report for the fiscal year ending December 31, 2024. The company is adjusting to incorporate the financial impacts of a debt-restructuring moratorium extended on September 25, 2025. GeNeuro aims to eventually provide updated information regarding the new dates for their financial publications.

Under Swiss law, a debt moratorium safeguards companies in financial distress, allowing them to restructure debts and negotiate with creditors effectively. During this period, GeNeuro is protected from creditor legal actions while striving for financial recovery under expert supervision. Possible outcomes include recapitalization or asset restructuring, but failure could lead to bankruptcy proceedings.